News | October 25, 2025
Syngene International expands capabilities with new bioconjugation suite in Bengaluru
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,
The U.S. FDA issued a Form 483 with five observations
This will be Aster’s fifth hospital in Bengaluru
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Plans underway to expand screening capacity by 50% for greater accessibility
Subscribe To Our Newsletter & Stay Updated
